Press Releases

Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates

Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates
6 July 2012 London and Lausanne, 6 July 2012 - Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and Switzerland-based ADC Therapeutics Sarl (ADCT)* announce today that they have signed agreements to develop cancer treatments called Antibody Drug Conjugates (ADCs) using CRT antibodies and peptides, and ADCT’s ‘warhead’ and linker chemistries. ADCs